Jennifer Brown, MD, PhDProfessor, Medicine
Tara Graff, DOMedical Oncologist
Bruton Tyrosine Kinase (BTK) Inhibitors have recently changed the treatment of CLL, but the efficacy of first-generation agents has been limited by relatively high adverse event and treatment discontinuation rates. Acalabrutinib, a selective, next-generation covalent BTK inhibitor approved for the treatment of patients with treatment-naive and relapsed/refractory CLL/small lymphocytic lymphoma (SLL), is hypothesized to have enhanced tolerability vs first-generation agents. Join Dr. Jennifer Brown and Dr. Tara Graff in this engaging webinar as they discuss the clinical implications of recent data on the efficacy and safety of acalabrutinib for the treatment of CLL from ASCO 2021.
*Review the efficacy of acalabrutinib in treatment-naïve and previously treated chronic lymphocytic leukemia
*Review the safety and tolerability of acalabrutinib in treatment-naïve and previously treated chronic lymphocytic leukemia
*Integrate new data into the development of treatment plans for chronic lymphocytic leukemia
The content for this program has been independently developed by Clinical Care Solutions.